CA
NZ
UK
AU
IND
US
Stephen G. Oswald, an officer and director of Ducommun Inc /DE/, filed a Form 144 notice of proposed sale of 2,000 shares of common stock, with an approximate sale date of November 9, 2026, through Charles Schwab Corp.
Amgen (NASDAQ:AMGN) disclosed new clinical and health economic data for Repatha (evolocumab) at the American Heart Association Scientific Sessions 2026 on November 9, 2026, covering cost-effectiveness analyses from the VESALIUS-CV trial and long-term cardiovascular outcomes from the FOURIER open-label extension study.
Hudson Bay Capital Management LP and Sander Gerber filed a Schedule 13G with the SEC on November 9, 2026, reporting beneficial ownership of Class A Ordinary Shares of Jones Ventures INTL Acquisition1 Corp as of September 30, 2026.
Jennifer Kong-Picarello, Senior Vice President and CFO of Terex Corporation, filed a Form 4 on November 9, 2026, disclosing the acquisition of 35 shares of Terex common stock on November 5, 2026, through the company's Deferred Compensation Plan.
A Form 144 notice of proposed securities sale was filed on November 9, 2026, disclosing that CME Group Inc. director Daniel G. Kaye intends to sell 532 shares of CME Group common stock through Fidelity Brokerage Services LLC.
Patrick S. Carroll, President of Environmental Solutions at Terex Corp, filed a Form 4 on November 9, 2026, reporting the acquisition of 64 shares of Terex common stock on November 5, 2026, through the company's Deferred Compensation Plan.
Esquire Financial Holdings, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 9, 2026, reporting third-quarter net income of $17,482 thousand and total assets that more than doubled year-over-year to $4,805,405 thousand.
Director Patrick L. Alexander of Landmark Bancorp Inc filed a Form 144 notice on November 9, 2026, disclosing a proposed sale of 1,000 shares of Landmark Bancorp common stock through RBC Capital Markets LLC on NASDAQ.
Director E. Philip Wenger of Fulton Financial Corp filed a Form 144 notice on November 9, 2026, disclosing a proposed sale of 5,000 shares of common stock from an IRA, with an approximate sale date of November 6, 2026, through Raymond James & Associates, …
Thomas K Equels, CEO and President of AIM ImmunoTech Inc., filed a Form 4 on November 9, 2026, disclosing a purchase of common stock on November 6, 2026.
Please wait processing your request...